URGN Relative Valuation
URGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, URGN is overvalued; if below, it's undervalued.
Historical Valuation
Urogen Pharma Ltd (URGN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.14. The fair price of Urogen Pharma Ltd (URGN) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：24.28
Fair
-15.70
PE
1Y
3Y
5Y
Trailing
Forward
-22.19
EV/EBITDA
Urogen Pharma Ltd. (URGN) has a current EV/EBITDA of -22.19. The 5-year average EV/EBITDA is -4.60. The thresholds are as follows: Strongly Undervalued below -12.01, Undervalued between -12.01 and -8.30, Fairly Valued between -0.89 and -8.30, Overvalued between -0.89 and 2.81, and Strongly Overvalued above 2.81. The current Forward EV/EBITDA of -22.19 falls within the Strongly Undervalued range.
-26.16
EV/EBIT
Urogen Pharma Ltd. (URGN) has a current EV/EBIT of -26.16. The 5-year average EV/EBIT is -4.75. The thresholds are as follows: Strongly Undervalued below -13.52, Undervalued between -13.52 and -9.13, Fairly Valued between -0.36 and -9.13, Overvalued between -0.36 and 4.03, and Strongly Overvalued above 4.03. The current Forward EV/EBIT of -26.16 falls within the Strongly Undervalued range.
5.64
PS
Urogen Pharma Ltd. (URGN) has a current PS of 5.64. The 5-year average PS is 4.35. The thresholds are as follows: Strongly Undervalued below 0.49, Undervalued between 0.49 and 2.42, Fairly Valued between 6.28 and 2.42, Overvalued between 6.28 and 8.20, and Strongly Overvalued above 8.20. The current Forward PS of 5.64 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Urogen Pharma Ltd. (URGN) has a current P/OCF of 0.00. The 5-year average P/OCF is -3.59. The thresholds are as follows: Strongly Undervalued below -13.53, Undervalued between -13.53 and -8.56, Fairly Valued between 1.38 and -8.56, Overvalued between 1.38 and 6.35, and Strongly Overvalued above 6.35. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
253.29
P/FCF
Urogen Pharma Ltd. (URGN) has a current P/FCF of 253.29. The 5-year average P/FCF is 5.45. The thresholds are as follows: Strongly Undervalued below -87.42, Undervalued between -87.42 and -40.99, Fairly Valued between 51.89 and -40.99, Overvalued between 51.89 and 98.32, and Strongly Overvalued above 98.32. The current Forward P/FCF of 253.29 falls within the Strongly Overvalued range.
Urogen Pharma Ltd (URGN) has a current Price-to-Book (P/B) ratio of -9.84. Compared to its 3-year average P/B ratio of -3.45 , the current P/B ratio is approximately 184.99% higher. Relative to its 5-year average P/B ratio of -0.45, the current P/B ratio is about 2089.34% higher. Urogen Pharma Ltd (URGN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -22.56%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -28.05% , the current FCF yield is about -100.00% lower.
-9.84
P/B
Median3y
-3.45
Median5y
-0.45
-12.12
FCF Yield
Median3y
-22.56
Median5y
-28.05
Competitors Valuation Multiple
The average P/S ratio for URGN's competitors is , providing a benchmark for relative valuation. Urogen Pharma Ltd Corp (URGN) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 9.04%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of URGN increased by 127.98% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -3.70 to -7.02.
The secondary factor is the Margin Expansion, contributed 29.18%to the performance.
Overall, the performance of URGN in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Urogen Pharma Ltd (URGN) currently overvalued or undervalued?
What is Urogen Pharma Ltd (URGN) fair value?
How does URGN's valuation metrics compare to the industry average?
What is the current P/B ratio for Urogen Pharma Ltd (URGN) as of Dec 05 2025?
What is the current FCF Yield for Urogen Pharma Ltd (URGN) as of Dec 05 2025?
What is the current Forward P/E ratio for Urogen Pharma Ltd (URGN) as of Dec 05 2025?